MannKind Corp

MNKD remains in a Stage 2 advancing regime with clear HH/HL structure and rising EMAs. After tests of resistance and slight extension, the recent pullback into the rising 9/21 EMA zone offers favorable entry opportunity. We recommend buying now on acceptance into these EMAs, aiming to participate in continuation of the uptrend. Key risk is failure of EMA support leading to a deeper pullback.

• ↑Afrezza pediatric label expands addressable market to 360,000 US children.
• ↑Q1 2026 revenue $90M, up 15% YoY; FUROSCIX sales $15.5M (+64%).
• ↓Q1 2026 GAAP net loss $16.6M underscores poor profitability conversion.